WCN25-1435 VISUALIZATION OF THE MESANGIAL-CELL-SURFACE AUTOANTIGENS IN IGA NEPHROPATHY

WCN25-1435 VISUALIZATION OF THE MESANGIAL-CELL-SURFACE AUTOANTIGENS IN IGA NEPHROPATHY

Saved in:

Bibliographic Details
Main Authors:	Kazuaki Mori, Yoshihito Nihei, Hitoshi Suzuki, Yusuke Suzuki
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924031243
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-2007 Evaluation of treatment strategy in patients with IgA nephropathy with impaired renal function
by: Ryousuke Aoki, et al.
Published: (2025-02-01)

WCN24-1104 Finding of CD4+ T cells infiltrating the kidney of gddY mouse, IgA nephropathy animal model
by: Hiroyuki Iwasaki, et al.
Published: (2024-04-01)

LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy
by: Koshi Yamada, et al.
Published: (2024-02-01)

WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-1709 Salivary and Urinary Metabolomics Study in IgA Nephropathy Patients
by: Rümeyza Kazancıoğlu, et al.
Published: (2025-02-01)

WCN25-4245 A CASE SERIES OF CONCURRENT IGA NEPHROPATHY AND ANTI- GBM DISEASE
by: Priyangani Lohia, et al.
Published: (2025-02-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-4235 CHRONICITY SCORE AND NOT MEST C SCORE IS A BETTER PREDICTOR OF PROGNOSIS IN IGA NEPHROPATHY
by: TULSI MODI, et al.
Published: (2025-02-01)

WCN25-1471 IgA Nephropathy with Anti-Neutrophil Cytoplasmic Antibodies in a Middle-Aged Patient
by: Giovanna Yazmin Arteaga Müller, et al.
Published: (2025-02-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-1435 LUPUS PODOCYTOPATHY: CASE SERIES OF 4 CASES FROM DOMINICAN REPUBLIC
by: Eliana Dina-Batlle, et al.
Published: (2024-04-01)

WCN24-186 JAK/STAT EXPRESSION IN PATIENTS WITH IGA NEPHROPATHY
by: Mateus Luvizotto, et al.
Published: (2024-04-01)

WCN24-1702 Mesangial Morphomics Analysis in Short-Looped and LongLooped Nephrons Using Artificial Intelligence in Diabetic Nephropathy
by: Haichun Yang, et al.
Published: (2024-04-01)

WCN25-4090 The Diagnostic potential of Serum Gd-IgA1 to C3 ratio in IgA nephropathy: A single center prospective study
by: Ravi tej Madipalli, et al.
Published: (2025-02-01)

WCN25-4466 Baseline parameters of IgA Nephropathy Using the Oxford MEST Score: Insights from the I-TANGIBLE Registry
by: Kavita Yadav, et al.
Published: (2025-02-01)

WCN24-2478 PODOCYTOPATHY ASSOCIATED WITH IGA NEPHROPATHY: IS IT REALLY A PROGNOSTIC FACTOR?
by: BELENGALLEGOS VAZQUEZ, et al.
Published: (2024-04-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN25-1128 IgA DOMINANT INFECTION RELATED GLOMERULONEPHRITIS
by: Fatima Alkindi, et al.
Published: (2025-02-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

WCN25-1664 Epidemiology, disease burden and treatment patterns for primary IgA nephropathy patients: A real-world data study in The Netherlands
by: Thom Lysen, et al.
Published: (2025-02-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-3679 Open label, single arm, multicenter, prospective study on oral enteric coated budesonide therapy for primary IgA nephropathy
by: SANSHRITI CHAUHAN, et al.
Published: (2025-02-01)

Corrigendum to “Redox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and Podocytes”
by: Gina Manda, et al.
Published: (2018-01-01)

Mesangial angiogenesis and interstitial eosinophilic infiltration in diabetic nephropathy are associated with elevated CD248 expression
by: Xiangmeng Li, et al.
Published: (2025-12-01)

A Case of IgA Nephropathy in a Patient With Sarcoidosis: Confirmation of Glomerular Galactose-Deficient IgA1 Deposition
by: Yoshitaka Shimizu, et al.
Published: (2025-01-01)

WCN24-889 BASILIXIMAB INDUCTION, STEROID USE AND RECURRENCE OF IGA NEPHROPATHY IN RENAL TRANSPLANT PATIENTS
by: Isabela Bertoni, et al.
Published: (2024-04-01)

WCN24-1347 CLINICAL PRESENTATION AT THE TIME OF DIAGNOSIS IN A COHORT OF MEXICAN PATIENTS WITH IGA NEPHROPATHY
by: Estefania Garduño Hernandez, et al.
Published: (2024-04-01)

Corrigendum to “Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review”
Published: (2025-07-01)

WCN25-932 STEROID (SYSTEMIC OR ENTERIC RELEASED BUDESONIDE) REFRACTORY NEPHROTIC RANGE PROTEINURIA IN IgA NEPHROPATHY; CAN TACROLIMUS BE AN ALTERNATIVE?- A CASE SERIES
by: RAJA SINGHAL, et al.
Published: (2025-02-01)

WCN25-3861 Is it Membranous nephropathy in a case of Primary APLA?
by: Rahul Sai Gangula, et al.
Published: (2025-02-01)

WCN25-925 A RARE CASE OF AN INHERITED CRYSTALLINE NEPHROPATHY
by: Jawad Iqbal Rather, et al.
Published: (2025-02-01)

Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy
by: Rachele Escoli, et al.
Published: (2015-01-01)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
by: Lisa Kivman, et al.
Published: (2025-02-01)

Opportunities and challenges in the treatment of IgA nephropathy
by: Yang Yang, et al.
Published: (2025-07-01)

Characterisation of IgA Nephropathy in an Australian Cohort
by: Shriram Swaminathan, et al.
Published: (2025-01-01)

WCN25-627 Effects of Irisin secretion on the development of renal injury in a mouse model of uremic sarcopenia
by: Teruyuki Okuma, et al.
Published: (2025-02-01)

Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01)

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
by: Qiang Sun, et al.
Published: (2016-01-01)